Skip to main content
Premium Trial:

Request an Annual Quote

Florida Atlantic University, Torrey Pines to Test Compounds for Cancer Drug Development

NEW YORK  (GenomeWeb News) — Florida Atlantic University and Torrey Pines Institute for Molecular Studies plan to study compounds discovered by TPIMS with an FAU genetic discovery related to three major cancers, FAU said yesterday.
 
Under the agreement, FAU and TPIMS will use a gene called SIM2, which has been associated with colon, prostate, and pancreatic cancers, at FAU’s Charles E. Schmidt College of Science to develop drugs.  
 
FAU said researchers at the CSCS have co-developed an assay to discover an inhibitor of the SIM2 gene, which will be screened against “thousands of compounds from TPIMS’ collection” for usefulness as a therapy.
 
FAU said the researchers will use Affymetrix’s GeneChip microarrays for the analysis.
 
According to CSCS, FAU “has the basic research and proof-of-concept in place,” and TPIMS has “the compounds and expertise to help expedite drug discovery.”

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.